Therefore, with the help of the models developed so far, the mechanism by which IL7R activating mutations lead to B-ALL has been understood in more detail, and this knowledge could now be used for the development of more specific therapies. This evidence concerns the gene IL7R and acute lymphoblastic leukemia.